Innovent Biologics, Inc. (HKG:1801)

Innovent Biologics Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 8, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	153,131	132,265	59,956	69,333	51,403	70,547
Market Cap Growth	91.96%	120.60%	-13.53%	34.88%	-27.14%	-38.71%
Enterprise Value	135,976	125,514	54,283	63,850	44,899	59,352
Last Close Price	88.25	76.25	36.60	42.75	33.50	48.25
PE Ratio	168.73	146.09	-	-	-	-
Forward PE	47.47	42.67	-	-	-	-
PS Ratio	10.55	9.11	5.98	10.14	9.98	13.46
PB Ratio	7.11	6.14	4.30	5.02	4.24	5.56
P/TBV Ratio	7.72	6.67	4.76	5.04	4.25	5.57
P/FCF Ratio	14.14	12.21	175.32	-	-	-
P/OCF Ratio	13.76	11.88	43.78	425.78	-	-
EV/Sales Ratio	9.37	8.65	5.41	9.34	8.72	11.33
EV/EBITDA Ratio	99.05	86.09	194.28	-	-	-
EV/EBIT Ratio	191.87	153.74	-	-	-	-
EV/FCF Ratio	12.56	11.59	158.73	-	-	-
Debt / Equity Ratio	0.14	0.14	0.22	0.29	0.30	0.24
Debt / EBITDA Ratio	2.12	2.12	9.62	-	-	-
Debt / FCF Ratio	0.29	0.29	8.81	-	-	-
Net Debt / Equity Ratio	-0.80	-0.80	-0.38	-0.59	-0.55	-0.63
Net Debt / EBITDA Ratio	-11.77	-11.77	-19.24	5.70	2.06	2.57
Net Debt / FCF Ratio	-1.58	-1.58	-15.72	7.56	2.11	2.11
Asset Turnover	0.44	0.44	0.45	0.33	0.27	0.30
Inventory Turnover	2.87	2.87	2.52	1.51	1.00	1.19
Quick Ratio	2.38	2.38	2.08	2.68	2.78	3.27
Current Ratio	2.63	2.63	2.35	3.00	3.29	3.79
Return on Equity (ROE)	5.01%	5.01%	-0.74%	-8.84%	-20.70%	-28.56%
Return on Assets (ROA)	1.56%	1.56%	-0.36%	-5.12%	-11.54%	-12.04%
Return on Invested Capital (ROIC)	18.05%	11.85%	-1.86%	-31.37%	-72.59%	-95.23%
Return on Capital Employed (ROCE)	2.50%	2.50%	-0.70%	-9.70%	-22.20%	-20.50%
Earnings Yield	0.59%	0.68%	-0.17%	-1.63%	-4.79%	-4.75%
FCF Yield	7.07%	8.19%	0.57%	-1.54%	-6.19%	-5.38%
Buyback Yield / Dilution	-6.98%	-6.98%	-4.35%	-4.67%	-2.37%	-7.27%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.